TransCode Therapeutics

RNAZ52

Penny Stock

$0.26arrow_drop_down4.00%-$0.01

Penny Stock

RNAZ52

$0.26

arrow_drop_down4.00%-$0.01

Penny Stock

Performance History

Key Stats
Open	$0.27
Prev. Close	$0.27
EPS	268.14
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$4.55M

	LOW	HIGH
Day Range	0.24	0.27
52 Week Range	0.21	128.00

Ratios

Revenue	-



EBITDA Margin %	-

EPS	268.14

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About TransCode Therapeutics (RNAZ)

TransCode Therapeutics, Inc. (RNAZ) is a biotechnology company that is focused on the development of RNA-targeted therapeutics. Their mission is to harness the power of RNA molecules to treat a variety of diseases. The company's lead product candidate, RNAZ, is a novel therapy designed to target specific disease-causing genes. By modulating the expression of these genes, RNAZ has the potential to provide therapeutic benefit in a range of indications. TransCode Therapeutics is dedicated to advancing RNA-based therapies through rigorous scientific research and clinical development.

RNAZ has shown promising preclinical results in multiple disease models, demonstrating its potential as a transformative therapy. TransCode Therapeutics is currently conducting Phase 1 clinical trials to evaluate the safety and efficacy of RNAZ in patients with specific genetic disorders. The company is also actively exploring potential partnerships and collaborations to further advance the development and commercialization of RNAZ. With a strong management team and a robust pipeline, TransCode Therapeutics is well-positioned to drive innovation in the field of RNA-targeted therapeutics.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Robert Michael Dudley
Headquarters: Boston
Employees: 19
Exchange: NASDAQ

Keep an eye on TransCode Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is TransCode Therapeutics's (RNAZ) price per share?

The current price per share for TransCode Therapeutics (RNAZ) is $0.26. The stock has seen a price change of -$0.01 recently, indicating a -4% change. This reflects the stock's recent market performance and investor sentiment.

help

Is TransCode Therapeutics (RNAZ) a growth stock?

TransCode Therapeutics (RNAZ) has shown an average price growth of 0.41% over the past three years. It has received a score of -7 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying TransCode Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is the 52-week high and low for TransCode Therapeutics (RNAZ)?

For TransCode Therapeutics (RNAZ), the 52-week high is $128, which is 48.38K% from the current price. The 52-week low is $0.22, the current price is 22.22% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

What is TransCode Therapeutics (RNAZ) stock price performance year to date (YTD)?

As of the latest data, TransCode Therapeutics (RNAZ) has a year-to-date price change of -95.91%. Over the past month, the stock has experienced a price change of 0.76%. Over the last three months, the change has been -80.3%. Over the past six months, the figure is -62.29%.

help

Is TransCode Therapeutics (RNAZ) a profitable company?

TransCode Therapeutics (RNAZ) has a net income of -$18.55M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$19.42M. Furthermore, the EBITDA is -$17.68M.

help

What is the market capitalization of TransCode Therapeutics (RNAZ)?

TransCode Therapeutics (RNAZ) has a market capitalization of $4.56M. The average daily trading volume is 1.96M, indicating the stock's liquidity and investor engagement.